Trends in hematological cancer in the elderly in Denmark, 1980–2012

Abstract Background The number of hematological malignancies is expected to increase as the Danish population ages within the next few decades. Despite this, data on the course of hematological cancers among the oldest patients are sparse with many intervention studies focusing on younger age groups. The aim of this study is to present Danish incidence and mortality rates among older patients with non-Hodgkin lymphomas (NHL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). Material and methods Nationwide population-based study presenting the incidence, prevalence and mortality rates of NHL, MM, and AML with a focus on the elderly population in Denmark during the last few decades. Data were drawn from the NORDCAN database. Results Incidence rates of NHL, MM, CLL and AML were 10–50 times higher among the population aged 70 years or more than among the younger population. An increasing incidence with stable or decreased mortality rates was seen mainly among elderly patients with NHL during the last few decades, leading to increased survival and a greater prevalence of patients with NHL. Increased relative survival and prevalence could also be seen among elderly patients with MM and CLL, while the trends of the incidence rates were inconclusive for these diseases. Survival among patients with AML improved most notably in those aged below 70 years leading to an increased prevalence of AML patients predominantly in this age group. Conclusion Improvements in diagnostics and treatment have led to increased survival and therefore prevalence of elderly patients with NHL, MM, CLL and AML during the past decades.

[1]  K. Christensen,et al.  Trends in cancer in the elderly population in Denmark, 1980–2012 , 2016, Acta oncologica.

[2]  A. Rao,et al.  Acute myeloid leukemia and myelodysplastic syndromes in older adults. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Michael Hallek,et al.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.

[4]  R. Stauder,et al.  The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. , 2014, Leukemia research.

[5]  H. Brenner,et al.  Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century , 2014, British journal of haematology.

[6]  S. Vincent Rajkumar,et al.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.

[7]  G. Colditz,et al.  Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. , 2013, Journal of geriatric oncology.

[8]  Stephanie J. Lee,et al.  Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Alexandra G. Smith,et al.  Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network , 2011, British Journal of Cancer.

[10]  Marianne Lundkjær Gjerstorff,et al.  The Danish Cancer Registry , 2011, Scandinavian journal of public health.

[11]  R. Sankila,et al.  Survival of European patients diagnosed with lymphoid neoplasms in 2000–2002: results of the HAEMACARE project , 2011, Haematologica.

[12]  F. Berrino,et al.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.

[13]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[14]  D. Boulware,et al.  Cancer in nonagenarians: profile, treatments and outcomes. , 2010, Critical reviews in oncology/hematology.

[15]  F. Bray,et al.  Trends in the survival of patients diagnosed with malignant neoplasms of lymphoid, haematopoietic, and related tissue in the Nordic countries 1964–2003 followed up to the end of 2006 , 2010, Acta oncologica.

[16]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[17]  E. Zucca,et al.  Management of elderly patients with hematological neoplasms. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  K. Rothman,et al.  Short‐term mortality of bacteraemia in elderly patients with haematological malignancies , 2006, British journal of haematology.

[19]  M. Nørgaard,et al.  The data quality of haematological malignancy ICD-10 diagnoses in a population-based Hospital Discharge Registry , 2005, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[20]  A. Langston,et al.  Update in acute leukemia 2003: a risk adapted approach to acute myeloblastic leukemia in adults. , 2004, Seminars in oncology.

[21]  D. Longo,et al.  Lymphoma and myeloma in older patients. , 2004, Seminars in oncology.

[22]  Paul W Dickman,et al.  Regression models for relative survival , 2004, Statistics in medicine.

[23]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[24]  R. Cartwright,et al.  TIME TRENDS IN INCIDENCE OF HAEMATOLOGICAL MALIGNANCIES AND RELATED CONDITIONS , 1999, British journal of haematology.

[25]  J. Hallas,et al.  Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006 , 2012 .

[26]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.